RT @ZskiTexas: “An Empirical Antigen Selection Method Identifies #Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive…

RT @TaliLev123: Watching the Educational Session: Neoantigen-directed cancer immunotherapies at #AACR21? ICYMI in @CD_AACR: An empirical an…

RT @TaliLev123: Watching the Educational Session: Neoantigen-directed cancer immunotherapies at #AACR21? ICYMI in @CD_AACR: An empirical an…

RT @TaliLev123: Watching the Educational Session: Neoantigen-directed cancer immunotherapies at #AACR21? ICYMI in @CD_AACR: An empirical an…

RT @TaliLev123: Watching the Educational Session: Neoantigen-directed cancer immunotherapies at #AACR21? ICYMI in @CD_AACR: An empirical an…

RT @TaliLev123: Watching the Educational Session: Neoantigen-directed cancer immunotherapies at #AACR21? ICYMI in @CD_AACR: An empirical an…

RT @TaliLev123: Watching the Educational Session: Neoantigen-directed cancer immunotherapies at #AACR21? ICYMI in @CD_AACR: An empirical an…

Watching the Educational Session: Neoantigen-directed cancer immunotherapies at #AACR21? ICYMI in @CD_AACR: An empirical antigen selection method identifies #neoantigens that either elicit broad anti-tumor T cell responses or drive tumor growth. https://t.

RT @ElizSMcKenna: ICYMI in @CD_AACR: An empirical antigen selection method identifies #neoantigens that either elicit broad anti-tumor T ce…

RT @ElizSMcKenna: ICYMI in @CD_AACR: An empirical antigen selection method identifies #neoantigens that either elicit broad anti-tumor T ce…

RT @ElizSMcKenna: ICYMI in @CD_AACR: An empirical antigen selection method identifies #neoantigens that either elicit broad anti-tumor T ce…

RT @ElizSMcKenna: ICYMI in @CD_AACR: An empirical antigen selection method identifies #neoantigens that either elicit broad anti-tumor T ce…

ICYMI in @CD_AACR: An empirical antigen selection method identifies #neoantigens that either elicit broad anti-tumor T cell responses or drive tumor growth @jessaflecht @GenoceaBio (Related to #AACR21 Poster 1762) https://t.co/Py7vsKr3tL

RT @CD_AACR: From the March issue: An empirical antigen selection method identifies #neoantigens that either elicit broad anti-tumor T cell…

RT @CD_AACR: From the March issue: An empirical antigen selection method identifies #neoantigens that either elicit broad anti-tumor T cell…

$GNCA #Neoantigens

RT @CD_AACR: From the March issue: An empirical antigen selection method identifies #neoantigens that either elicit broad anti-tumor T cell…

RT @CD_AACR: From the March issue: An empirical antigen selection method identifies #neoantigens that either elicit broad anti-tumor T cell…

From the March issue: An empirical antigen selection method identifies #neoantigens that either elicit broad anti-tumor T cell responses or drive tumor growth. @jessaflecht @GenoceaBio https://t.co/ATidJxed4n https://t.co/vzdkRAaqo6

🆕 Cancer Immunotherapy Research. $PSNL and $TWST, among others, played a role in the results. An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth | Cancer Discovery https:/

RT @matemanc: Unexpectedly high prevalence of neopeptides that potentially promote #tumor progression by inducing suppressive T cell respon…

RT @rongejman: Very interesting work. https://t.co/O6ruM25ZL4

Very interesting work. https://t.co/O6ruM25ZL4

Unexpectedly high prevalence of neopeptides that potentially promote #tumor progression by inducing suppressive T cell responses. https://t.co/3VrGksDzfw #cancer #immunotherapy #vaccine #vaccines

🆕"Sequencing and data analysis were performed at Personalis, which have demonstrated accuracy and precision of their experimental protocols, with a sensitivity of 99% for SNVs" $PSNL https://t.co/32WtAnFMQf https://t.co/kBaFjyx7ZV

Q4’20 Earnings Call tomorrow 8:30 AM EST; Phase 2 GEN-009 + CPI (Opdivo/Keytruda data Pres’n at AACR’21 in April and/or ASCO’21 in June.$GNCA #Genocea #GNCA

RT @GenoceaBio: Genocea’s ATLAS™ platform is proving to be an invaluable tool in identifying what does & doesn’t belong in an immunotherapy…

$GNCA The most undervalued biotech on the planet. Game-changing cancer immunotherapy platform sitting at a market cap of $150M; $2.92 pps. $GME #Silver #WSB #GME #Biotech $IBB $NBI #Cancer #Immunotherapy #Genocea

RT @GenoceaBio: #ICYMI, we shared our recent @CD_AACR publication showing GEN-009 generated broad CD4 & 8 T cell responses to 99% of the va…

Genocea’s ATLAS is gold. “An empirical antigen selection method (ATLAS) identifies neoantigens that either elicit broad anti-tumor T cell responses or drive tumor growth” https://t.co/ZmvusziGT6 $GNCA #Cancer #Immunotherapy Genocea is the most undervalue

An empirical antigen selection method identifies neoantigens that either elicit broad anti-tumor T cell responses or drive tumor growth. https://t.co/seTeJ04lnc

RT @CD_AACR: Just published #OnlineFirst: An empirical antigen selection method identifies #neoantigens that either elicit broad anti-tumor…

Wow 👀

Just published #OnlineFirst: An empirical antigen selection method identifies #neoantigens that either elicit broad anti-tumor T cell responses or drive tumor growth. @jessaflecht @GenoceaBio https://t.co/Yjr1wy8ILx https://t.co/gyKoA1f6Wg